Luly Jay R.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Dec 10, 2024
- Accession no.
- 0001062993-24-020375
- Filed
- Dec 10, 2024
- Trade date
- Dec 6, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $41.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luly Jay R.CIK 0001571211 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2024 | Common Stock | SSaleDisposed | −5,142 | $8.06 | −$41,444.52 | 801,638 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.